Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders

Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello

Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Journal Issue: October
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello. Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders. Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020

Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015

Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011

Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Year: 2019

Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence
Source: Eur Respir J 2010; 36: 709-711
Year: 2010

The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017

Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity
Source: Eur Respir J 2006; 27: 230-232
Year: 2006

The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1426-1433
Year: 2015

Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009

Experience of using Janus kinase inhibitors in COVID-19
Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment
Year: 2021

Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020

Role of IκB kinases (IKKs) α and β in severe asthma and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 2s
Year: 2005

Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study
Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018
Year: 2019

Increased activation of p38 MAPK in COPD
Source: Eur Respir J 2008; 31: 62-69
Year: 2008

Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
Source: Eur Respir J 2013; 41: 3-4
Year: 2013

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Source: Eur Respir Rev 2017; 26: 160004
Year: 2017

Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010

Pulmonary hypertension in patients with chronic myeloproliferative disorders
Source: Eur Respir Rev 2015; 24: 400-410
Year: 2015